Get leading-edge coverage of Alzheimer’s research and drug development with STAT+

Get your first 3 months of STAT+ for $30 and access up-to-date information about Alzheimer's disease and treatment. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

www.statnews.com We've spent years following Alzheimer's disease research and providing STAT readers with extensive coverage of significant drug developments and frustrating failures. To mark this World Alzheimer's Day, get your first 3 months of STAT+ for $30 and stay up-to-date on Alzheimer's disease research and treatment. SUBSCRIBE Meet some of our biotech reporters:   Adam Feuerstein Senior Writer, Biotech   Damian Garde National Biotech Reporter Check out our latest Alzheimer's disease coverage: FDA approves first Alzheimer's therapy shown to clearly slow cognitive decline by Adam Feuerstein and Damian Garde Researchers turn to CRISPR to unlock one of the trickiest diseases to treat: Alzheimer's by Andrew Joseph As Alzheimer's drugs hit the market, the race for early detection blood tests heats up by Brittany Trang Medicare wants to improve Alzheimer's care, but sidesteps drug prices by John Wilkerson READ MORE Wednesday, September 20, 2023       1 Exchange Place, Boston, MA 02109 ©2023, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us